GLP-1 injection pen beside a glass of red wine and research charts illustrating a new survey on GLP-1 users drinking less alcohol.
|

GLP-1 Users Say They’re Drinking Less. Here’s What the New Research Actually Shows

Published October 26, 2026 · By The Recover Editorial Team

A growing number of people taking GLP-1 medications such as semaglutide say something unexpected happened after they started: they began drinking less alcohol. A nationally representative survey published this month in JAMA Psychiatry puts some of the first population-level data behind those reports. At the same time, larger clinical trials, including one run by the U.S. Department of Veterans Affairs and two Phase 3 studies sponsored by Eli Lilly, are now enrolling to test whether this effect holds up under rigorous conditions.

Here is what the new findings show, what they cannot prove yet, and why none of it changes the basic safety picture for someone who drinks heavily today.

Key Takeaways

  • A JAMA Psychiatry research letter published October 14, 2026, surveyed 2,009 U.S. adults. Among the 242 who were drinking when they started a GLP-1 medication, those with potentially unhealthy alcohol use were more than twice as likely to report cutting back within three months.
  • The survey relies on self-report, so it shows an association. It does not prove the medication caused the change.
  • The VA has begun enrolling more than 600 veterans at 18 medical centers in a placebo-controlled semaglutide trial for alcohol use disorder.
  • Eli Lilly is running two Phase 3 trials of an investigational drug, brenipatide, for alcohol use disorder, with results not expected before 2028.
  • No GLP-1 medication is FDA-approved to treat alcohol use disorder, and none treats alcohol withdrawal.

What the New JAMA Psychiatry Survey Found

Researchers from the Brown University School of Public Health, RAND, Harvard Medical School, McLean Hospital, Duke and Brandeis surveyed members of the RAND American Life Panel in 2026. The sample of 2,009 adults was designed to be nationally representative. Participants were asked whether they had used a GLP-1 medication, how their drinking changed afterward, and whether they knew these drugs might affect alcohol use. The findings appeared as a research letter titled Patient-Reported Changes in Alcohol Use Following Glucagon-Like Peptide-1 Receptor Agonist Initiation.

The team focused on the 242 people who were drinking at the time they started the medication and looked at self-reported changes during the first three months. Two findings stand out:

  • People whose drinking already met the threshold for potentially unhealthy use were significantly more likely to report drinking less after starting a GLP-1, with an adjusted odds ratio of 2.30.
  • That same group was also more likely to already know that GLP-1 drugs may reduce the urge to drink.

The authors noted that a notable share of GLP-1 users in the survey reported reductions, while stressing that large clinical trials are still needed before drawing conclusions about cause and effect.

Why This Survey Matters, and What It Cannot Prove

Most early evidence on GLP-1 drugs and alcohol has come from two places: small clinical trials and electronic health records. This survey adds something neither of those captures well, which is how real-world patients describe their own drinking after starting the medication.

That is also its main limitation. Self-reported drinking is prone to recall errors and to people underestimating what they drink. There is a second issue worth considering. The heavier drinkers in this survey were more aware of the possible link between GLP-1s and alcohol. People who expect to want less alcohol may notice and report changes more readily, or may make a deliberate effort to cut back at the same time they start a new medication. A survey cannot separate those effects from the drug itself.

Weight loss goals are another factor. Many GLP-1 users are trying to lose weight, and cutting alcohol calories is a common part of that effort. A randomized, placebo-controlled trial is the only way to isolate what the medication is doing on its own.

Other Real-World Signals Point the Same Direction

The JAMA Psychiatry survey is not the only observational data suggesting a link.

NIH All of Us cohort

An analysis of the National Institutes of Health’s All of Us research program, also published in JAMA Psychiatry, examined 15,447 participants with GLP-1 prescription records. People with active prescriptions had modestly lower scores on a standard alcohol screening questionnaire. The difference appeared to come from drinking on fewer days rather than from drinking less per occasion or binge drinking less.

UK consumer data

In the United Kingdom, the alcohol education charity Drinkaware and research consultancy KAM surveyed 207 current or former GLP-1 users in February 2026. In their report, Drinking Differently, users said their average drinking frequency fell from 3.1 to 2.2 days per week after starting the medication. About a third reported reduced cravings, and 18% said they experienced nausea or other discomfort when drinking.

The trend has reached the alcohol industry as well. Brewers including Heineken have flagged GLP-1 use as a factor in shifting demand toward smaller serves and low- or no-alcohol drinks. Industry interest is not medical evidence, but it does show how widely the pattern is being noticed.

The Large Trials That Could Settle the Question

Observational data can raise a question. Only well-designed trials can answer it. Several large studies are now underway.

The VA semaglutide trial

In August 2026, the U.S. Department of Veterans Affairs announced a clinical trial called the Cessation or Reduction of Alcohol Consumption in Veterans trial. It plans to enroll more than 600 veterans between the ages of 18 and 80 with moderate or severe alcohol use disorder at 18 VA medical centers, from Seattle and Palo Alto to Houston, Atlanta and Philadelphia. Participants receive weekly injections of semaglutide or a placebo for 24 weeks, followed by a safety follow-up period. Recruitment began August 17, 2026.

The VA noted that more than 400,000 veterans are diagnosed with alcohol use disorder. It pointed to a March 2026 analysis that found lower rates of alcohol and other substance use disorders among patients taking GLP-1 drugs compared with similar patients on other diabetes medications. The department also explicitly discouraged veterans from self-medicating or replacing existing alcohol treatment with GLP-1 drugs.

Eli Lilly’s brenipatide Phase 3 program

Eli Lilly is testing an investigational injectable called brenipatide in two Phase 3, randomized, double-blind, placebo-controlled trials. RENEW-ALC-1 enrolls adults with moderate-to-severe alcohol use disorder and includes a later phase testing whether people who respond can maintain their reduced drinking. RENEW-ALC-2 enrolls adults with alcohol use disorder and hazardous drinking, with an enrollment goal of 1,100 participants ages 18 to 75. Participation lasts about 56 weeks, and the listed study dates run through April 2028.

Phase 3 trials are the final stage of testing before a company can seek FDA approval for a new use. Results from these studies will carry far more weight than any survey.

The table below summarizes the major studies discussed in this article.

StudyTypeWhoStatus / key finding
JAMA Psychiatry survey (Oct 2026)Nationally representative survey2,009 U.S. adults; 242 drinking at GLP-1 startUnhealthy drinkers more likely to report cutting back (aOR 2.30)
NIH All of Us analysisHealth-record cohort15,447 people with GLP-1 prescriptionsModestly lower screening scores, driven by fewer drinking days
Drinkaware / KAM (UK)Consumer survey207 GLP-1 usersDrinking days fell from 3.1 to 2.2 per week (self-reported)
The Lancet (2026)Randomized trial108 adults with AUD and obesityHeavy drinking days fell 13.7 points more than placebo
VA veterans trialRandomized trial600+ veterans, 18 VA sitesEnrolling since Aug 2026
Lilly RENEW-ALC-1 and -2Phase 3 randomized trialsAdults with AUD (ALC-2 target: 1,100)Recruiting; dates run through 2028

Where the Clinical Evidence Stands Today

The strongest controlled evidence so far comes from a 26-week trial published in The Lancet in 2026. It involved 108 treatment-seeking adults who had both alcohol use disorder and obesity, and every participant also received cognitive behavioral therapy. Semaglutide reduced heavy drinking days by about 13.7 percentage points more than placebo (PubMed record).

A smaller eight-week trial of oral semaglutide, published in the American Journal of Psychiatry, missed its primary laboratory endpoint for cue-triggered craving but showed fewer heavy drinking days and lower everyday cravings on secondary measures.

For a full breakdown of each trial, its limitations, and how semaglutide compares with existing medications, see our in-depth guide: Ozempic for Alcohol Addiction? What New Semaglutide Research Shows.

The regulatory picture has not changed. No GLP-1 medication is FDA-approved to treat alcohol use disorder. The FDA has also warned consumers about unapproved and illegally marketed GLP-1 products sold online.

What This Means If You or Someone You Love Drinks Heavily

Headlines about GLP-1 drugs and alcohol can make it sound as though a simple fix is close. The research does not support that conclusion yet, and a few points matter for anyone affected by alcohol use right now.

Reduced cravings are not the same as safe withdrawal. Someone who drinks heavily every day can face serious medical risks if they stop suddenly, whether or not they are taking a GLP-1. Our guides explain why alcohol withdrawal can be dangerous, how to tell a hangover from withdrawal, and why withdrawal can get worse with each episode.

Proven options already exist. The FDA has approved several medications for alcohol use disorder, and they work best alongside counseling and support. The National Institute on Alcohol Abuse and Alcoholism tracks both approved medications and the search for new ones. You can also read about medications used in addiction treatment.

A prescriber should be part of any medication decision. If you already take a GLP-1 and have noticed changes in your drinking, that is worth discussing honestly with the clinician who prescribes it.

Treatment for alcohol use disorder can range from medically supervised detox to residential rehab to intensive outpatient programs that fit around work and family. When depression, anxiety or trauma are part of the picture, dual diagnosis treatment addresses both at once. Families looking for a starting point can review our resources on helping a loved one and how insurance covers rehab.

Frequently Asked Questions

Do GLP-1 drugs make people drink less?

Many users report drinking less, and early randomized trials have found reductions in heavy drinking for some participants. The newest survey data shows an association, not proof that the medication causes the change. Large placebo-controlled trials now underway are designed to answer that question.

What did the October 2026 JAMA Psychiatry study find?

In a nationally representative survey of 2,009 U.S. adults, GLP-1 users who were drinking at unhealthy levels when they started the medication were more than twice as likely to report cutting back within three months. They were also more likely to already know the drugs might affect alcohol use.

Is Ozempic approved to treat alcohol use disorder?

No. Semaglutide, the active ingredient in Ozempic and Wegovy, is approved for diabetes and weight-related conditions. It is not FDA-approved for alcohol use disorder.

What is brenipatide?

Brenipatide is an investigational injectable medication that Eli Lilly is testing for alcohol use disorder in two Phase 3 trials, RENEW-ALC-1 and RENEW-ALC-2. It has not been approved for any use.

Can veterans join the VA GLP-1 alcohol trial?

The VA trial is enrolling veterans ages 18 to 80 with moderate or severe alcohol use disorder at 18 VA medical centers. Veterans can ask their local VA medical center or search ClinicalTrials.gov for details on eligibility and locations.

Finding Help Today

You do not need to wait for new research to get support. TheRecover.com helps individuals and families understand detox, inpatient and outpatient treatment options and connect with programs that fit their needs. Call (888) 510-3898 for confidential treatment navigation. You can also find licensed programs through FindTreatment.gov or call the free, confidential SAMHSA National Helpline at 1-800-662-4357. If you are in crisis, call or text 988. More options are listed on our crisis resources page.

Related coverage: Why Overdose Deaths Are Falling · Mirtazapine as a Medication for Meth Addiction · More Addiction News

Sources

Editorial note: This article reports on published research and public announcements and was prepared under TheRecover.com’s editorial standards. It is for educational purposes and does not provide medical advice. Semaglutide and brenipatide are not FDA-approved to treat alcohol use disorder. Do not start, stop or change a medication, or stop heavy drinking abruptly, without guidance from a qualified healthcare professional.

Similar Posts